利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎患者的疗效和安全性：来自德国登记处（GRAID）的结果。
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
机构信息
Department of Rheumatology and Clinical Immunology, University of Würzburg, Würzburg, Germany.
出版信息
J Rheumatol. 2012 Nov;39(11):2153-6. doi: 10.3899/jrheum.120482. Epub 2012 Sep 15.
OBJECTIVE
Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV.
METHODS
Clinical and safety data of patients with AAV treated with RTX were retrospectively assessed from the data of a German national registry.
RESULTS
In total, 58 patients were included in this analysis (50/58 with granulomatosis with polyangiitis; 8/58 with microscopic polyangiitis who received at least 1 cycle, 17 patients who received 2 cycles, and 3 patients who received 3 cycles of RTX). Response was classified as complete and partial in 22 (40%) and in 29 cases (52.7%), respectively. Four patients (7.3%) were classified as nonresponders.
CONCLUSION
RTX was well tolerated with good clinical efficacy in patients with refractory AAV.
目的
利妥昔单抗（RTX）治疗是难治性抗中性粒细胞胞浆抗体（ANCA）相关性血管炎（AAV）患者的一种治疗选择。我们研究了 RTX 在一组难治性 AAV 患者中的耐受性和临床疗效。
方法
从德国国家登记处的数据中回顾性评估了接受 RTX 治疗的 AAV 患者的临床和安全性数据。
结果
本分析共纳入 58 例患者（50/58 例为肉芽肿性多血管炎；8/58 例为显微镜下多血管炎，至少接受 1 个周期，17 例接受 2 个周期，3 例接受 3 个周期 RTX）。缓解分别在 22 例（40%）和 29 例（52.7%）中被分类为完全和部分缓解。4 例（7.3%）被归类为无反应者。
结论
RTX 在难治性 AAV 患者中具有良好的耐受性和良好的临床疗效。
Zotero 插件